Treace Medical Concepts, Inc. (TMCI) SEC Filings & Earnings Calls

Revenue decline of 4% YoY in Q2 2026; guidance implies continued decline for full year.

“Revenue for the second quarter of 2026 was $45.4 million, representing a decrease of 4% compared to $47.4 million in the second quarter of 2025” · word for word

Elective surgery demand sensitivity to macro conditions

“Inflation, the ongoing military conflict in the Middle East, recession fears, reduced consumer confidence, higher insurance deductibles, fuel prices and other costs, and other adverse economic conditions have negatively impacted, and may continue to negatively impact, consumer demand for elective foot and ankle surgeries.” · word for word

Product mix shift to lower-priced systems

“While adoption of these new systems is increasing, they are generally sold at lower average selling prices than our Lapiplasty System.” · word for word

High accumulated deficit and debt burden

“an accumulated deficit of $282.8 million and $60.0 million of principal outstanding under our term loan and revolving loan agreements.” · word for word

Revenue Decline and Mix Shift

“Revenue decreased by $5.4 million, or 10.2% ... driven by a mix shift from higher priced flagship Lapiplasty bunion procedure kits to lower priced minimally invasive bunion procedure kits and lower volume.” · word for word

Intense Competition

“We are also experiencing a shift in patient and surgeon preferences for treating less severe bunions through minimally invasive osteotomy solutions as well as MTP fusions, with competitive products already addressing these types of surgery.” · word for word

Litigation Costs and Uncertainty

“The increase in general and administrative expenses was due to a $2.1 million increase in legal fees primarily driven by ongoing litigation matters” · word for word

Macroeconomic Demand Pressure

“Inflation, recession fears, reduced consumer confidence, higher insurance deductibles, fuel prices and other costs, and other adverse economic conditions have negatively impacted, and may continue to negatively impact, consumer demand for elective foot and ankle surgeries.” · word for word

High Debt and Interest Burden

“Long-term debt, net $55,820 ... Interest expense $1,570”

Revenue decline and continued losses raise going-concern risk if cash burn does not improve as guided

“Revenue -10% YoY; net loss $(18.0)M; adj EBITDA loss $(5.5)M; cash burn reduction of ~50% expected for FY26”

Product mix shift headwinds: demand driven shift within expanded bunion portfolio may pressure gross margins.

“Updated guidance reflects headwinds from demand driven product and price mix shift within the Company’s expanded bunion portfolio.”

CCO departure and restructuring of commercial leadership could disrupt sales execution.

“Chief Commercial Officer departs; role not filled; SVP Sales now reports to CEO.”

Debt covenant default risk

“Under the terms of our loan agreements... we are subject to certain affirmative and negative covenants, including (but not limited to), financial covenants related to minimum revenue and minimum liquidity... Our lenders may also declare us in default for certain types of events... which would give them the right to declare all borrowings outstanding... to be” · word for word

Product concentration risk

“Our revenue is primarily generated from sales of the Lapiplasty System, and we are, therefore, highly dependent on it and the market acceptance and growth of our other existing and new products for our success.” · word for word

Competitive bundling risk

“Our sales have been and may continue to be adversely affected due to larger competitors utilizing their established contracts and dominant market positions in unrelated service lines to induce customers to buy their bunion correction systems instead of our products through purchase commitments, rebate payments and/or volume-based pricing agreements.” · word for word

Revenue decline guidance for FY2026 due to product mix shift and pricing pressure.

“FY2026 revenue guidance of $200-212M represents a decline of 6-0% YoY.”

Adjusted EBITDA loss expected to widen in FY2026.

“FY2026 adjusted EBITDA loss of $4-6M vs $3.9M loss in FY2025.”

Dependence on surgeon adoption and market share gains for growth recovery.

“Company expects market share gains and product launches to restore growth in H2 2026.”

Revenue decline in Q4 2025 and no FY2026 guidance signal demand headwinds from economic conditions and consumer sentiment.

“headwinds related to broader economic conditions and softer consumer sentiment, as well as a product mix shift.” · word for word

Preliminary results subject to adjustment; may change after audit.

“The preliminary unaudited financial information in this press release has not been subject to the more rigorous standards of review...remains subject to change” · word for word

Flagship product decline

“our flagship Lapiplasty System is experiencing lower sales primarily due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, and lower patient demand for elective bunion surgery due to macroeconomic conditions.” · word for word

Non-recurring stocking distributor revenue

“Revenue for the three months ended September 30, 2025 included $6.0 million in sales to stocking distributors, a majority of which was attributable to initial stocking orders ... we do not expect sales at this level in future quarters.” · word for word

Cash burn and liquidity

“Net cash used in operating activities for the nine months ended September 30, 2025 was $7.9 million ... cash and cash equivalents of $7.7 million and marketable securities of $49.7 million.” · word for word

Litigation cost escalation

“General and administrative expenses increased by $2.8 million, or 20.4% ... due to a $2.9 million increase in legal fees primarily driven by ongoing litigation matters.” · word for word

Surgeon preference shift to minimally invasive surgery (MIS) is reducing demand for flagship Lapiplasty product.

“Lapiplasty volumes have been impacted as surgeons and patient preferences shift towards minimally invasive solutions.” · word for word

Macroeconomic conditions and softer consumer sentiment are causing deferrals of elective bunion procedures.

“We are seeing broader macroeconomic conditions and softer consumer sentiment resulting in a greater number of deferrals of elective bunion procedures.” · word for word

Competition is increasing, pressuring market share.

“The Company’s reduction in full-year 2025 guidance is primarily a result of expected lower sales from its flagship Lapiplasty System, largely due to ... competition.”